GET DAILY SIGNALSAXON Down -25% YTD Despite Strong Growth: Contrasting It With SEER's Early-Stage Profile
Key Takeaways
- AXON (Axon Enterprise) stands as a profitable, large-cap leader in public-safety technology, posting revenue growth above 30% year over year, while SEER (Seer, Inc.) remains a small-cap life-sciences firm with modest revenue and ongoing losses.
- Axon has lifted its full-year revenue outlook in recent quarters, yet its shares sit roughly 25% lower year-to-date and about 43% lower over the trailing year despite solid fundamentals.
- Seer reaffirmed 2026 revenue guidance of $16–18 million and maintains a sizable cash position relative to its market value, though it continues to burn cash in a challenging academic funding climate.
- The companies operate in distinct sectors—public safety versus proteomics—making the comparison useful for investors evaluating growth at a premium against speculative early-stage positioning.
- For additional detail on each ticker's major headlines and daily trading activity, explore AXON Major News and AXON Today's Price Move, plus SEER Major News and SEER Today's Price Move.
- To observe how automated strategies are positioned across the market, explore Trending AI Robots.
Setting the Context for AXON and SEER
Axon Enterprise (AXON) and Seer, Inc. (SEER) represent contrasting ends of the equity landscape, each drawing interest from investors pursuing distinct growth stories. Axon has established itself as a profitable force in law-enforcement and public-safety technology, whereas Seer is still an early-stage player developing proteomics tools on the path to profitability. Placing them side by side highlights two separate risk-and-reward dynamics: one centered on a premium growth compounder and the other on a speculative small-cap backed by substantial cash and an unfolding commercial narrative. Growth-oriented investors, momentum participants, and those comparing performance across market caps may find this analysis relevant right now.
AXON Overview and Recent Performance
Axon Enterprise (AXON) leads globally in public-safety technology, linking TASER devices, body-worn and in-car cameras, drones and counter-drone systems, digital evidence management, and AI-powered software. Recent quarters have shown revenue expansion above 30% year over year, with annual recurring revenue reaching approximately $1.6 billion, net revenue retention close to 126%, and future contracted bookings surpassing $15 billion. Management has increased its full-year 2026 revenue guidance, pointing to strength in software, international markets, and enterprise segments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Even with this progress, the stock has underperformed lately. Shares have hovered near the $420–$425 range, down roughly 25% year-to-date and about 43% over the trailing year, following the launch of its Axon Body 5 camera at a major law-enforcement event in late October. Investors seem to be balancing a premium valuation—long supported by high-margin software and AI adoption—against pressures from tariffs, memory costs, and a shifting hardware mix. Analyst views stay largely positive, with a consensus Buy rating and an average price target above current levels, as the market absorbs execution details versus expectations.
SEER Overview and Recent Performance
Seer, Inc. (SEER) focuses on life sciences through its Proteograph platform, enabling deep, unbiased proteomics for biomarker discovery and large-scale studies with academic, biobank, and biopharmaceutical clients. Recent updates feature a collaboration profiling 10,000 samples in a Singapore population study, a doubling of independent peer-reviewed publications, and a positive patent ruling that strengthens its intellectual-property stance.
Financially, Seer stays small and unprofitable. First-quarter 2026 revenue fell 34% year over year to roughly $2.8 million amid weak academic funding and competition, alongside a net loss of about $16.8 million. The company reaffirmed its full-year 2026 revenue guidance of $16–18 million. Its balance sheet offers support, with approximately $220 million in cash and investments at the end of the first quarter—exceeding its market capitalization and providing a multi-year runway. Shares have traded near $1.90 recently, within a 52-week range of about $1.55 to $2.41, carrying event-driven risks from a rejected take-private offer and an ongoing shareholder contest.
Head-to-Head Comparison
The core difference lies in business model and maturity. Axon (AXON) produces hundreds of millions in quarterly revenue with expanding recurring software revenue and positive adjusted EBITDA, while Seer (SEER) is still establishing commercial traction with quarterly revenue in the low single-digit millions and persistent losses. Axon funds its growth through operations and a substantial backlog, whereas Seer relies on its cash reserves and share-buyback approach.
Risks diverge as well. For Axon, these include government budget cycles, valuation sensitivity, and margin impacts from hardware mix and component costs. For Seer, they revolve around cash burn, reliance on a soft academic funding environment, competitive pressures, and governance questions from an activist campaign. Sector exposure widens the gap: Axon ties to public-safety and defense spending, while Seer operates in life sciences and diagnostics. Axon provides scale and consistency at a demanding valuation, whereas Seer offers optionality and asset-backed support but limited near-term revenue clarity.
Tickeron AI Verdict
Considering factors such as trend consistency, relative stability, and underlying catalysts, Tickeron's AI would likely lean toward AXON over SEER currently. Axon's above-30% revenue growth, high net revenue retention, large contracted backlog, and generally favorable analyst consensus point to a more resilient trend, even amid valuation compression. Seer holds a stronger cash position relative to its market value yet shows less consistent momentum, negative free cash flow, and event-driven uncertainty. This view remains probabilistic: Axon's scale and steadiness currently outweigh Seer's speculative potential, though Seer's catalysts could shift the balance if commercial progress accelerates.
Using Tickeron AI Trading Bots for Strategy Testing
In my own research process, I have found Tickeron's AI Trading Bots helpful for evaluating automated approaches on names like these. The platform hosts hundreds of bots with varying styles, timeframes, and performance histories, allowing users to compare how different strategies align with current market conditions and specific tickers. This can provide a structured way to explore relative positioning without replacing individual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AXON's RSI Oscillator recovers from oversold territory
The RSI Indicator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 24 of the 27 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AXON as a result. In 63 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 27 of 39 cases over the following month. The odds of a continued upward trend are 69%.
Following a +2.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.415) is normal, around the industry mean (4.846). AXON has a moderately high P/E Ratio (172.417) as compared to the industry average of (16.894). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement